[99mTc]Tc-N4-asp-MJ9

[99mTc]Tc-N4-asp-MJ9 is a radiopharmaceutical research compound developed for the molecular imaging of tumors that overexpress the gastrin-releasing peptide receptor (GRPR), such as prostate cancer. The molecule consists of the MJ9 peptide, a potent GRPR antagonist, conjugated to a 6-carboxy-1,4,8,11-tetraazaundecane (N4) chelator through a D-aspartate (asp) linker. As a radiotracer for Single-Photon Emission Computed Tomography (SPECT), it is labeled with the gamma-emitting radioisotope technetium-99m. It binds with high affinity to GRPR, allowing for the visualization of malignant tissues with high contrast. Preclinical evaluations in PC-3 tumor-bearing mice have demonstrated that this compound possesses high radiochemical purity and favorable pharmacokinetic properties, including high tumor uptake and improved tumor-to-background contrast in the abdominal region compared to earlier generation bombesin analogs like Demobesin 4.

Other names

technetium-99m labeled N4-asp-MJ9technetium99m labeled N4-asp-MJ9technetium 99m labeled N4-asp-MJ96-carboxy-1,4,8,11-tetraazaundecane-asp-MJ9 labeled with technetium-99m